From the WSJ, Feb 17th 2009, When a Llama is Laid Back, It's Not the Only Beneficiary (p. A11), about the extremly small size of antibodies in llamas and camels, and the company Ablynx that is developing them for diagnostics and therapies:

"A major problem is that it sounds too good to be true, said Serge Muyldermans [one of the founders of Ablynx]... 'The only disadvantage [our antibodies] have is we can't find a disadvantage. People don't believe us anymore.' " [emphasis added.]

So the notion that Biocurex's anti-RECAF antibody faces the very same professional or institutional incredulity is, well, quite credible, as Dr. Moro has already here testified.

Now, in re Ablynx's research into these tiniest of antibodies:

1., Would Ablynx more likely be a competitor with Biocurex, or a collaborator?

2., Do 'small antibodies' have the potential to augment and/or compliment our anti-RECAF antibody?